Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171522 · ClinicalTrials.gov registry record · Phase 4
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
A Phase 4 study of Constipation, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 14
- Study locations
NCT00171522: Completed Phase 4 study of Constipation, sponsored by Novartis.
NCT00171522 is a Phase 4 study of Constipation that has completed, run by Novartis. The registered enrollment target is 52 participants, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00171522, a Phase 4 study of Constipation, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 14
- Study locations
Study Summary
To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste
Conditions Studied
Interventions
- DRUG Tegaserod and Polyethylene Glycol 3350
Study Locations (14)
Arizona
- Harmony Clinical Research - Oro Valley
- Central Phoenix Medical Clinic, LLC - Phoenix
- Adobe Gastroenterology, PC - Tucson
Virginia
- National Clinical Research, Inc - Richmond
- East Coast Clinical Research - Virginia Beach
California
- Associated Pharmaceutical Research Center, Inc - Buena Park
Florida
- Clinical Trial Management of Boca Raton, Inc. - Boca Raton
Kansas
- Health Science Center - Pratt
Massachusetts
- Beth Israel Deacon Medical Center - Boston
Nebraska
- Heartland Clinical Research, Inc - Omaha
New Jersey
- MBS Clinical Research, LLC - Margate City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 4 |
What the finished NCT00171522 record still lists
NCT00171522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which Tegaserod and Polyethylene Glycol 3350 is the first listed.
NCT00171522 lists 14 locations in 11 states (Arizona, Virginia, California).
Frequently Asked Questions
What is clinical trial NCT00171522 about?
NCT00171522 is a clinical study titled "Preference of Tegaserod vs. PEG 3350 in Patients With Constipation". To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste
What is the current status of trial NCT00171522?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2005-05. Estimated completion is 2005-09.
What conditions does trial NCT00171522 study?
This clinical trial studies the following conditions: Constipation.
What interventions are being tested in trial NCT00171522?
The interventions under investigation include: Tegaserod and Polyethylene Glycol 3350 (DRUG).
Who is sponsoring clinical trial NCT00171522?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171522 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00171522's enrollment target sits among peer trials
52 32nd of 54 higher than 22 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery
RECRUITING · Phase 4
-
Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients
COMPLETED · Phase 4
-
An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients
COMPLETED · Phase 4
-
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia